Toward a More Precise Future for Oncology

Cancer Cell. 2020 Apr 13;37(4):431-442. doi: 10.1016/j.ccell.2020.03.014.

Abstract

Prospective molecular characterization of cancer has enabled physicians to define the genomic changes of each patient's tumor in real time and select personalized therapies based on these detailed portraits. Despite the promise of such an approach, previously unrecognized biological and therapeutic complexity is emerging. Here, we synthesize lessons learned and discuss the steps required to extend the benefits of genome-driven oncology, including proposing strategies for improved drug design, more nuanced patient selection, and optimized use of available therapies. Finally, we suggest ways that next-generation genome-driven clinical trials can evolve to accelerate our understanding of cancer biology and improve patient outcomes.

Keywords: clinical trial design; drug development; genome-driven oncology; precision oncology.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / genetics*
  • Drug Development*
  • Genomics
  • Humans
  • Molecular Targeted Therapy*
  • Neoplasms / diagnosis*
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Patient Selection*
  • Precision Medicine

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor